Trisialoganglioside GT1b (GT1b)

Trisialoganglioside GT1b is a major sialic acid-containing glycosphingolipid predominantly expressed in the outer leaflet of neuronal membranes in the central and peripheral nervous systems [2, 9]. It belongs to the b-series of gangliosides and is one of the four most abundant gangliosides in the mammalian brain, playing essential roles in neuronal maturation, synaptic stability, and axon-myelin interactions through its binding to myelin-associated glycoprotein (MAG) [5, 9]. GT1b serves as a critical high-affinity receptor for potent neurotoxins, including Botulinum and Tetanus toxins, facilitating their entry into neurons [6, 17]. Beyond its structural and receptor roles, GT1b has been identified as an endogenous agonist for Toll-like receptor 2 (TLR2), where its upregulation following nerve injury triggers microglial activation and contributes to the development of neuropathic pain [1, 11]. Alterations in GT1b levels and the presence of anti-GT1b autoantibodies are clinically significant in neurodegenerative disorders like Alzheimer's and Parkinson's diseases, as well as autoimmune neuropathies such as the Miller Fisher variant of Guillain-Barré syndrome [2, 13]. Therapeutic interest in GT1b involves both its use as a target for pain management and the administration of related gangliosides like GM1 for neuroprotection [3, 10].

Other names

Polysialoganglioside GT1bGanglioside GT1bII3(NeuAc)2,IV3NeuAc-Gg4CerNeuronal ganglioside GT1b

GT1b functions as a high-affinity receptor for clostridial neurotoxins (Botulinum and Tetanus), an endogenous agonist for Toll-like receptor 2 (TLR2) in the induction of neuropathic pain, and a modulator of neurotrophin signaling (TrkA) and axon-myelin stability through interactions with myelin-associated glycoprotein (MAG).